Referring Clinician
Please email all referrals to CentralReferral@adhb.govt.nz (including Att: ACTC in email subject)
Email us for any other queries: infoACTC@adhb.govt.nz
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| Advanced solid tumours with established IO indication | BGB-A317-A445-101 | Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | BGB-A445 (OX40 agonist) and Tislelizumab (PD-1 inhibitor) Three weekly infusions | • Phase 1a: Dose Escalation: Includes BGB-A445 monotherapy cohorts and combination cohorts with tislelizumab. Recruitment opens intermittently. • Dose Expansion: Closed until phase 1a completed. Details to follow. | Phase 1a recruiting |
| Metastatic Melanoma | MK1308-001 (Checkmate 76U) | A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab | MK1308A (Co-formulation of MK1308 (CTLA4 inh) + pembrolizumab | -Cohort J o Unresectable stage III or metastatic melanoma o Confirmed progression on scan after PD1/PDL1 monotherapy or in combination with other therapies excluding prior CTLA4 inhibitor exposure. o BRAF v600 mutation positive disease accepted provided that participants have/ are still receiving targeted therapy OR remains asymptomatic with no evidence of rapid progression and LDH ON HOLD |
|